Anne ABRIAT-HEMMENDINGER appointed to the Board of Directors of DEINOVE
May 21 2019 - 1:00AM
- Her proven experience in the beauty industry, particularly
within the L'Oréal Group, will be a key asset in DEINOVE's
innovation approach
- This appointment underlines the importance of the bioactive
compounds and the cosmetics market in the Company's strategy
DEINOVE (Euronext Growth Paris: ALDEI), a French
biotech company that uses a disruptive approach to develop
innovative antibiotics and bio-based active ingredients for
cosmetics and nutrition, announced the appointment of Anne
ABRIAT-HEMMENDINGER as a member of the Board of
Directors.
Anne ABRIAT-HEMMENDINGER has more than 30 years
of experience in product development for the beauty industry, for
brands with an international outlook. She is highly competent in
the development of ingredients for the cosmetic, food, nutrition
and wellness industries. She has worked for various prestigious
brands, notably within the L'Oréal and Coty Groups where she has
led numerous innovation projects. In 2012, she founded The Smell
& Taste Lab, a consulting company specialized in innovation and
marketing for cosmetics, nutrition and well-being. Anne
ABRIAT-HEMMENDINGER holds a Master's degree in Organic Chemistry
from ESCOM (École Supérieure de Chimie Organique et Minérale).
The Shareholders’ Meeting of DEINOVE, held on
May 20th, ratified the appointment of Anne ABRIAT-HEMMMENDINGER as
a member of the Board of Directors, replacing Mr. Michaël CARLOS.
She will hold office for the remainder of her predecessor's term of
office, i.e. until the general meeting called to approve the
financial statements for the 2019 financial year.
Anne ABRIAT-HEMMENDINGER is a member of the
Swiss Women Directors' Circle and APIA Switzerland (Associate
Independent Professional Directors).
Anne ABRIAT-HEMMENDINGER said:
"I am very interested in DEINOVE's extremely innovative approach to
create new active ingredients from the untapped potential of
bacteria. I am delighted to put my expertise at the service of the
Company's ambitions. "
ABOUT DEINOVE
DEINOVE is a French biotechnology company, a
leader in disruptive innovation, which aims to help meet the
challenges of antibiotic resistance and the transition to a
sustainable production model for the cosmetics and nutrition
industries.
DEINOVE has developed a unique and comprehensive
expertise in the field of rare bacteria that it can decipher,
culture, and optimize to disclose unsuspected possibilities and
induce them to produce biobased molecules with activities of
interest on an industrial scale. To do so, DEINOVE has been
building and documenting since its creation an unparalleled
biodiversity bank that it exploits thanks to a unique technological
platform in Europe.
DEINOVE is organized around two areas of
expertise:
- ANTIBIOTICS, new-generation anti-infective
agents: DEINOVE is preparing to enter a first antibiotic
candidate into Phase II. The Company is also pursuing the
systematic exploration of biodiversity to supply its portfolio with
new leads, drawing notably on partnerships with Naicons,
bioMérieux, Proteus and Institut Pasteur (AGIR program supported by
Bpifrance).
- BIOACTIVES, Active ingredients of natural
origin with cosmetics as the first market and potential in
nutrition and health: DEINOVE already markets a first innovative
active ingredient, a second in partnership with Greentech, while
two others are in development with Oléos (Hallstar Group). It also
runs a program in animal nutrition with Groupe Avril. Several other
partnerships are also being planned.
Within the Euromedecine science park located in
Montpellier, DEINOVE employs 62 employees, mainly researchers,
engineers, and technicians, and has filed more than 260 patent
applications internationally. The Company has been listed on
EURONEXT GROWTH® since April 2010.
CONTACTS
InvestorsCoralie
MartinCommunication, Marketing and Investor Relations Ph.:
+33 (0)4 48 19 01 60coralie.martin@deinove.com
MediaALIZE
RPCaroline Carmagnol / Aurore Gangloff / Catherine
MégélasPh.: +33 (0)1 44 54 36 66deinove@alizerp.com
- 190521_PR_Appointment_AABRIAT